<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
  <title>Peptide News | Klow Peptide</title>
  <link>https://klow-peptide.com/en/news/</link>
  <atom:link href="https://klow-peptide.com/en/news/feed.xml" rel="self" type="application/rss+xml"/>
  <description>Peptide and GLP-1 news from official sources: clinical trial results, drug approvals, regulatory changes and safety alerts, country by country.</description>
  <language>en</language>
  <lastBuildDate>Sun, 15 Nov 2026 08:20:28 GMT</lastBuildDate>
  <image><url>https://klow-peptide.com/logo-512x512.png</url><title>Klow Peptide</title><link>https://klow-peptide.com/en/news/</link></image>
  <item>
    <title>Semaglutide associated with lower food noise scores in two real-world telehealth studies</title>
    <link>https://klow-peptide.com/en/news/semaglutide-food-noise-obesityweek-2026-studies/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/semaglutide-food-noise-obesityweek-2026-studies/</guid>
    <pubDate>Sun, 15 Nov 2026 08:20:28 GMT</pubDate>
    <description>On November 14, 2026, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy injection or Wegovy pill.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/semaglutide-food-noise-obesityweek-2026-studies-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Novo Nordisk registers AMBITION 3, a Phase 3 trial of zenagamtide against semaglutide in type 2 diabetes</title>
    <link>https://klow-peptide.com/en/news/zenagamtide-vs-semaglutide-ambition-3-phase-3/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/zenagamtide-vs-semaglutide-ambition-3-phase-3/</guid>
    <pubDate>Fri, 13 Nov 2026 08:43:18 GMT</pubDate>
    <description>Novo Nordisk A/S submitted AMBITION 3, a Phase 3 study comparing once weekly zenagamtide with once weekly semaglutide in participants with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both, to ClinicalTrials.gov on 6 November 2026.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/zenagamtide-vs-semaglutide-ambition-3-phase-3-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Wegovy linked to greater AST and weight reductions in two real-world MASH analyses</title>
    <link>https://klow-peptide.com/en/news/semaglutide-real-world-mash-data-aasld/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/semaglutide-real-world-mash-data-aasld/</guid>
    <pubDate>Sat, 07 Nov 2026 08:26:18 GMT</pubDate>
    <description>Novo Nordisk announced on 6 November 2026 new real-world data from the retrospective PLATINUM-Truveta and RHODIUM-2 studies of Wegovy, its once weekly semaglutide injection, in adults with metabolic dysfunction-associated steatohepatitis (MASH), presented at the American Association for the Study of Liver Diseases, The Liver Meeting 2026, in Denver, Colorado.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/semaglutide-real-world-mash-data-aasld-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>HHS sets interim enforcement discretion for 503A compounding of six peptides</title>
    <link>https://klow-peptide.com/en/news/hhs-503a-compounding-six-peptides-policy/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/hhs-503a-compounding-six-peptides-policy/</guid>
    <pubDate>Sat, 07 Nov 2026 01:46:05 GMT</pubDate>
    <description>The US Department of Health and Human Services announced in the Federal Register, as of October 30, 2026, a draft enforcement discretion policy under which it does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding six listed peptide bulk drug substances under section 503A of the FD&amp;C Act.</description>
    <category>Regulation</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/hhs-503a-compounding-six-peptides-policy-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Thymosin beta-4 eye drop RGN-259 enters two simultaneous phase 3 trials in neurotrophic keratitis</title>
    <link>https://klow-peptide.com/en/news/tb-500-rgn-259-phase-3-keratitis/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/tb-500-rgn-259-phase-3-keratitis/</guid>
    <pubDate>Fri, 06 Nov 2026 08:38:20 GMT</pubDate>
    <description>RegeneRx says on its RGN-259 page that its U.S. joint venture ReGenTree LLC has initiated phase 3 trials in the U.S. and EU of RGN-259, an eye drop based on thymosin beta-4, in neurotrophic keratitis, with initial results targeted for early 2024, after top line results from the first phase 3 trial (SEER-1) were reported in May 2020.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/tb-500-rgn-259-phase-3-keratitis-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Malaysia's health ministry says GLP-1 treatment still has no dedicated allocation</title>
    <link>https://klow-peptide.com/en/news/glp-1-malaysia-no-dedicated-allocation/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/glp-1-malaysia-no-dedicated-allocation/</guid>
    <pubDate>Tue, 03 Nov 2026 08:17:49 GMT</pubDate>
    <description>Malaysia's Ministry of Health (KKM) will keep working to obtain a dedicated allocation to widen access to GLP-1 treatment with drugs such as Ozempic and Mounjaro, Health Minister Datuk Seri Dr Dzulkefly Ahmad said in Parliament, in remarks reported on 2 November 2026.</description>
    <category>Regulation</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/glp-1-malaysia-no-dedicated-allocation-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Retatrutide is tested head to head against semaglutide in Phase 3 TRANSCEND-T2D-2</title>
    <link>https://klow-peptide.com/en/news/retatrutide-semaglutide-phase-3-transcend-t2d-2/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/retatrutide-semaglutide-phase-3-transcend-t2d-2/</guid>
    <pubDate>Sun, 01 Nov 2026 08:20:05 GMT</pubDate>
    <description>The ClinicalTrials.gov record for TRANSCEND-T2D-2, Eli Lilly and Company's Phase 3 open-label study of once-weekly retatrutide compared with once-weekly semaglutide in adults with type 2 diabetes, was verified in September 2026 as active and no longer recruiting.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/retatrutide-semaglutide-phase-3-transcend-t2d-2-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Semaglutide: Novo Nordisk opens a Phase 4 kidney and heart study in China</title>
    <link>https://klow-peptide.com/en/news/semaglutide-phase-4-kidney-heart-trial-china/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/semaglutide-phase-4-kidney-heart-trial-china/</guid>
    <pubDate>Fri, 30 Oct 2026 08:16:53 GMT</pubDate>
    <description>Novo Nordisk A/S has a Phase 4 study of once weekly subcutaneous semaglutide in adults in China with type 2 diabetes and chronic kidney disease listed as recruiting on ClinicalTrials.gov, with the record first posted on 28 October 2026.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/semaglutide-phase-4-kidney-heart-trial-china-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Phase 3 AMPLIFY-2 will compare the EloraTZP coformulation with tirzepatide alone</title>
    <link>https://klow-peptide.com/en/news/tirzepatide-eloratzp-amplify-2-phase-3-trial/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/tirzepatide-eloratzp-amplify-2-phase-3-trial/</guid>
    <pubDate>Thu, 22 Oct 2026 07:30:31 GMT</pubDate>
    <description>Eli Lilly and Company registered AMPLIFY-2, a Phase 3 study of the eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide in adults with obesity or overweight and type 2 diabetes, in a ClinicalTrials.gov record first submitted on 12 October 2026 and first posted on 19 October 2026.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/tirzepatide-eloratzp-amplify-2-phase-3-trial-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Orforglipron's highest dose showed greater weight loss than one oral semaglutide dose in an indirect comparison</title>
    <link>https://klow-peptide.com/en/news/orforglipron-vs-oral-semaglutide-indirect-comparison/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/orforglipron-vs-oral-semaglutide-indirect-comparison/</guid>
    <pubDate>Mon, 12 Oct 2026 07:37:52 GMT</pubDate>
    <description>Eli Lilly and Company announced on September 29, 2026 the results of an indirect treatment comparison in which its highest orforglipron (Foundayo) dose was associated with greater weight loss and greater A1C reduction than the comparator oral semaglutide dose at 52 weeks in adults with type 2 diabetes.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/orforglipron-vs-oral-semaglutide-indirect-comparison-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
  <item>
    <title>Retatrutide lowers weight and A1C in Phase 3 TRIUMPH-2 trial</title>
    <link>https://klow-peptide.com/en/news/retatrutide-triumph-2-phase-3-results/</link>
    <guid isPermaLink="true">https://klow-peptide.com/en/news/retatrutide-triumph-2-phase-3-results/</guid>
    <pubDate>Thu, 08 Oct 2026 12:00:00 GMT</pubDate>
    <description>Eli Lilly and Company announced detailed results from the Phase 3 TRIUMPH-2 trial of retatrutide on September 29, 2026, reporting weight loss and A1C reductions at 80 weeks in adults with type 2 diabetes and obesity or overweight.</description>
    <category>Clinical trial</category>
    <media:content url="https://klow-peptide.com/images/content/news-cards/retatrutide-triumph-2-phase-3-results-en.jpg" medium="image" type="image/jpeg" width="1200"/>
  </item>
</channel>
</rss>
